Literature DB >> 27720456

Impact of Stress Testing for Coronary Artery Disease Screening in Asymptomatic Patients With Diabetes Mellitus: A Community-Based Study in Olmsted County, Minnesota.

Ruth E Bates1, Mohamed Omer2, Sahar S Abdelmoneim2, Adelaide M Arruda-Olson2, Christopher G Scott3, Kent R Bailey3, Robert B McCully2, Patricia A Pellikka4.   

Abstract

OBJECTIVE: To evaluate the impact of screening stress testing for coronary artery disease in asymptomatic patients with diabetes in a community-based population. PATIENTS AND METHODS: This observational study included 3146 patients from Olmsted County, Minnesota, with no history of coronary artery disease or cardiac symptoms in whom diabetes was newly diagnosed from January 1, 1992, through December 31, 2008. With combined all-cause mortality and myocardial infarction as the primary outcome, weighted Cox proportional hazards regression was performed with screening stress testing within 2 years of diabetes diagnosis as the time-dependent covariate. For descriptive analysis, participants were classified by their clinical experience during the first 2 years postdiagnosis as screened (asymptomatic, underwent stress test), unscreened (asymptomatic, no stress test), or symptomatic (experienced symptoms or event).
RESULTS: Among the screened and unscreened participants, 54% (1358 of 2538) were men; the mean (SD) age at diabetes diagnosis was 55 years (13.8 years), and 97% (2442 of 2520) had type 2 diabetes. In event-free survival analysis, 292 patients comprised the screened cohort and 2246 patients comprised the unscreened cohort. Death or myocardial infarction occurred in 454 patients (32 patients in the screened cohort and 422 in the unscreened cohort [5-year rate, 1.9% and 5.3%, respectively]) during median (interquartile range) follow-up of 9.1 years (5.3-12.5 years). Screening stress testing was associated with improved event-free survival (hazard ratio, 0.61; P=.004), independent of cardiac risk factors. However, while stress test results were abnormal in 47 of the 292 screened patients (16%), only 6 (2%) underwent coronary revascularization.
CONCLUSION: Although screening cardiac stress testing in asymptomatic patients with diabetes in this community-based population was associated with improvement in long-term event-free survival, this result does not appear to occur by coronary revascularization alone.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27720456      PMCID: PMC5524205          DOI: 10.1016/j.mayocp.2016.07.013

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  26 in total

Review 1.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Authors:  S M Grundy; I J Benjamin; G L Burke; A Chait; R H Eckel; B V Howard; W Mitch; S C Smith; J R Sowers
Journal:  Circulation       Date:  1999-09-07       Impact factor: 29.690

2.  ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).

Authors:  Lars Rydén; Peter J Grant; Stefan D Anker; Christian Berne; Francesco Cosentino; Nicolas Danchin; Christi Deaton; Javier Escaned; Hans-Peter Hammes; Heikki Huikuri; Michel Marre; Nikolaus Marx; Linda Mellbin; Jan Ostergren; Carlo Patrono; Petar Seferovic; Miguel Sousa Uva; Marja-Riita Taskinen; Michal Tendera; Jaakko Tuomilehto; Paul Valensi; Jose Luis Zamorano; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Guy De Backer; Per Anton Sirnes; Eduardo Alegria Ezquerra; Angelo Avogaro; Lina Badimon; Elena Baranova; Helmut Baumgartner; John Betteridge; Antonio Ceriello; Robert Fagard; Christian Funck-Brentano; Dietrich C Gulba; David Hasdai; Arno W Hoes; John K Kjekshus; Juhani Knuuti; Philippe Kolh; Eli Lev; Christian Mueller; Ludwig Neyses; Peter M Nilsson; Joep Perk; Piotr Ponikowski; Zeljko Reiner; Naveed Sattar; Volker Schächinger; André Scheen; Henrik Schirmer; Anna Strömberg; Svetlana Sudzhaeva; Juan Luis Tamargo; Margus Viigimaa; Charalambos Vlachopoulos; Robert G Xuereb
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

3.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

4.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

5.  Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group.

Authors: 
Journal:  Am J Cardiol       Date:  1997-01-15       Impact factor: 2.778

6.  Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.

Authors:  Joseph B Muhlestein; Donald L Lappé; Joao A C Lima; Boaz D Rosen; Heidi T May; Stacey Knight; David A Bluemke; Steven R Towner; Viet Le; Tami L Bair; Andrea L Vavere; Jeffrey L Anderson
Journal:  JAMA       Date:  2014-12-03       Impact factor: 56.272

7.  Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.

Authors:  Leon A Adams; Scott Harmsen; Jennifer L St Sauver; Phunchai Charatcharoenwitthaya; Felicity B Enders; Terry Therneau; Paul Angulo
Journal:  Am J Gastroenterol       Date:  2010-02-09       Impact factor: 10.864

8.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

9.  Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy.

Authors:  Michael J Zellweger; Michael Maraun; Hans H Osterhues; Ulrich Keller; Jan Müller-Brand; Raban Jeger; Otmar Pfister; Thilo Burkard; Friedrich Eckstein; Stefanie von Felten; Stefan Osswald; Matthias Pfisterer
Journal:  JACC Cardiovasc Imaging       Date:  2014-09-17

10.  Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.

Authors:  Timothy M E Davis; Ruth L Coleman; Rury R Holman
Journal:  Circulation       Date:  2013-01-29       Impact factor: 29.690

View more
  2 in total

1.  Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings.

Authors:  Rafael Y Brzezinski; Inbal Etz-Hadar; Ayelet Grupper; Michal Ehrenwald; Itzhak Shapira; David Zeltser; Shlomo Berliner; Ori Rogowski; Roy Eldor; Shani Shenhar-Tsarfaty
Journal:  Cardiovasc Diabetol       Date:  2017-06-23       Impact factor: 9.951

2.  Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation.

Authors:  Satish Arora; Anne Pernille Ofstad; Geir R Ulimoen; Kåre I Birkeland; Knut Endresen; Lars Gullestad; Odd Erik Johansen
Journal:  Cardiovasc Diabetol       Date:  2019-03-09       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.